Gary Bird

Gary Bird is EVP, Quality & Regulatory Affairs and is responsible for all CMC manufacturing activities to confirm regulatory and GMP compliance. His organization is responsible for creating a compliant quality system to meet US FDA expectations. He has over 30 years in the pharmaceutical and biotechnology industries with a broad area of expertise in regulatory affairs, quality system analysis, FDA compliance, team leadership, continuous improvement, and vendor relations.

Throughout his executive career, Dr. Bird has held leadership positions at pharmaceutical and biotech-related organizations, including the Food and Drug Administration (CDER and CBER). Eli Lilly and Company, GTx Incorporated, Geno Rx, and his consulting firms PharmaConsult US and PharmaConsult Global, Ltd. He represented both FDA and Industry in the International Conference on Harmonization (ICH) negotiations activities in five different Quality topic areas. He has authored and delivered numerous lectures and training courses as part of his industry and consulting services on subjects including best manufacturing practices for biopharmaceutical products, introduction to GMPs, introduction to biosafety, and stability of biopharmaceutical products.

Dr. Bird holds a PhD in Entomology and Biochemistry from Mississippi State University.